MED Price Chart
Loading chart...
50 DMA150 DMA200 DMA
MEDMedifast, Inc.
$11.83
Financials
AVOID
Investment Thesis
MED is a market laggard (RS 24/99, Top 76%) with declining fundamentals. avoid chasing - protect capital. Smart traders skip this one until the setup improves.
Weak relative strength + ordinary growth = Pass
Key Takeaways
- Earnings weak
- RS 24 - market laggard
- No base pattern
- Wait & watch
Earnings Momentum
Earnings Declining
Price Structure
Broken StructurePrice
$11.83
✓→
50 DMA
$11.31
→
100 DMA
$12.42
→
150 DMA
$12.90
→
200 DMA
$12.93
Alignment Score: 1/4
LEADERSHIP TEST FAILED
RS Rating 24/99 is in Bottom 24% of market. Minervini target: Top 20% (RS 80+)
Why Not BUY Yet?
RS Rating
24 (Top 76%)→>80 (Top 20%)
EPS Growth
-310%→>25% Qtr YoY
Pattern
No base forming→VCP or constructive base
Trend
Downtrend→Above 200 DMA
What Would Change Our Mind?
To turn bullish on MED, we need:
- RS Rating: >80 (Top 20%)(currently 24 (Top 76%))
- EPS Growth: >25% Qtr YoY(currently -310%)
- Pattern: VCP or constructive base(currently No base forming)
- Trend: Above 200 DMA(currently Downtrend)
Twin Engines Dashboard
Technical Health
RS Rating
24/99
Top 76% (Need 80+)
Trend
Downtrend
Below 200 DMA
RSI (14)
56
NEUTRAL
VCP Setup
COOL
Score: 3/9
Volume
254K
+1% vs avg
Breakout
None
No recent breakout
Fundamental Horsepower
EPS Qtr YoY
-310%
Declining
EPS 3Y CAGR
-76%
Annual Earnings
Revenue Qtr
-36%
DECLINING
F-Score
6/9
Piotroski Quality
ROE
1%
Return on Equity
EPS Rank
15/99
Percentile
If/Then Playbook
IF: RS Rating improves to >80
THEN: Re-evaluate for WATCHLIST
IF: Price closes below 200 DMA
THEN: Remove from radar entirely
IF: EPS growth accelerates to >40% next quarter
THEN: Reassess as potential turnaround
Key Price Levels
Resistance
- 200 DMA$12.93+9.3%
- 52W High$16.66+40.8%
Current$11.83
Support
- 50 DMA$11.31-4.4%
- 20 DMA$11.25-4.9%
- 52W Low$10.10-14.6%
More MED Analysis
Frequently Asked Questions
Is MED stock a buy now?
MED is a market laggard (RS 24/99, Top 76%) with declining fundamentals. avoid chasing - protect capital. Smart traders skip this one until the setup improves.
What is the buy point for MED?
MED currently has no confirmed breakout. Wait for a VCP pattern breakout with volume at least 40% above average before determining an actionable buy point.
What is MED's RS Rating?
MED has an RS Rating of 24/99, meaning it's in the Top 76% of all stocks for relative price performance over the past 12 months. Minervini recommends RS 80+ for momentum trades.
Important Disclosure: This analysis is for educational and informational purposes only. Technical and fundamental indicators are based on historical data and do not guarantee future performance. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.